Review





Similar Products

96
Miltenyi Biotec peptivator sars cov 2 prot s peptide pool
Peptivator Sars Cov 2 Prot S Peptide Pool, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peptivator sars cov 2 prot s peptide pool/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
peptivator sars cov 2 prot s peptide pool - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

95
Addgene inc sars cov
Sars Cov, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars cov/product/Addgene inc
Average 95 stars, based on 1 article reviews
sars cov - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

96
Miltenyi Biotec sars cov 2 peptide pools
Sars Cov 2 Peptide Pools, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars cov 2 peptide pools/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
sars cov 2 peptide pools - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

94
Miltenyi Biotec peptivator sars cov 2 prot s b 1 617 2 mutation
A) Experimental design and sample collection. Created in part with BioRender under CC BY license, Nelson, C., (2025). B) Quantification of total lung lesions detected with 18 FDG-PET/CT imaging at the peak of the response, per animal and per group with mean. Animal #ID represented by color and shape in legend. C) Example 18 FDG-PET/CT images from control animal #DGT7 and GC treated animal #DHXD. D) Quantification of the lung lesion volume (dot size) and the metabolic intensity (normalized FDG uptake = SUV of lesion/SUV muscle). Significance calculated with 2way Anova multiple comparison test at the indicated timepoints between GC treatment and control. E) Quantification of subgenomic RNA <t>of</t> <t>the</t> <t>SARS-CoV-2</t> N1 protein in copies per mL of BAL fluid. Individual animals and the mean of each group with standard error mean represented. Significance calculated with 2way Anova. Fold change between GC treatment and control indicated. Limit of detection (LOD) is 2,000 copies/mL fluid. F) Subgenomic N1 in copies per gram of tissue in the pulmonary lymph nodes, PET+ involved lung, and PET- uninvolved lung. Significance calculated with 2way Anova multiple comparison test. LOD is 1,000 copies per gram of tissue. p > 0.05 not shown, *p < 0.05, ***p < 0.001.
Peptivator Sars Cov 2 Prot S B 1 617 2 Mutation, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peptivator sars cov 2 prot s b 1 617 2 mutation/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
peptivator sars cov 2 prot s b 1 617 2 mutation - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

96
Miltenyi Biotec peptide olp pools
A) Experimental design and sample collection. Created in part with BioRender under CC BY license, Nelson, C., (2025). B) Quantification of total lung lesions detected with 18 FDG-PET/CT imaging at the peak of the response, per animal and per group with mean. Animal #ID represented by color and shape in legend. C) Example 18 FDG-PET/CT images from control animal #DGT7 and GC treated animal #DHXD. D) Quantification of the lung lesion volume (dot size) and the metabolic intensity (normalized FDG uptake = SUV of lesion/SUV muscle). Significance calculated with 2way Anova multiple comparison test at the indicated timepoints between GC treatment and control. E) Quantification of subgenomic RNA <t>of</t> <t>the</t> <t>SARS-CoV-2</t> N1 protein in copies per mL of BAL fluid. Individual animals and the mean of each group with standard error mean represented. Significance calculated with 2way Anova. Fold change between GC treatment and control indicated. Limit of detection (LOD) is 2,000 copies/mL fluid. F) Subgenomic N1 in copies per gram of tissue in the pulmonary lymph nodes, PET+ involved lung, and PET- uninvolved lung. Significance calculated with 2way Anova multiple comparison test. LOD is 1,000 copies per gram of tissue. p > 0.05 not shown, *p < 0.05, ***p < 0.001.
Peptide Olp Pools, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peptide olp pools/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
peptide olp pools - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

96
Miltenyi Biotec spike peptide pool
A) Experimental design and sample collection. Created in part with BioRender under CC BY license, Nelson, C., (2025). B) Quantification of total lung lesions detected with 18 FDG-PET/CT imaging at the peak of the response, per animal and per group with mean. Animal #ID represented by color and shape in legend. C) Example 18 FDG-PET/CT images from control animal #DGT7 and GC treated animal #DHXD. D) Quantification of the lung lesion volume (dot size) and the metabolic intensity (normalized FDG uptake = SUV of lesion/SUV muscle). Significance calculated with 2way Anova multiple comparison test at the indicated timepoints between GC treatment and control. E) Quantification of subgenomic RNA <t>of</t> <t>the</t> <t>SARS-CoV-2</t> N1 protein in copies per mL of BAL fluid. Individual animals and the mean of each group with standard error mean represented. Significance calculated with 2way Anova. Fold change between GC treatment and control indicated. Limit of detection (LOD) is 2,000 copies/mL fluid. F) Subgenomic N1 in copies per gram of tissue in the pulmonary lymph nodes, PET+ involved lung, and PET- uninvolved lung. Significance calculated with 2way Anova multiple comparison test. LOD is 1,000 copies per gram of tissue. p > 0.05 not shown, *p < 0.05, ***p < 0.001.
Spike Peptide Pool, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/spike peptide pool/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
spike peptide pool - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

96
Miltenyi Biotec peptivator sars cov 2 prot s complete wildtype spike peptide pool
A) Experimental design and sample collection. Created in part with BioRender under CC BY license, Nelson, C., (2025). B) Quantification of total lung lesions detected with 18 FDG-PET/CT imaging at the peak of the response, per animal and per group with mean. Animal #ID represented by color and shape in legend. C) Example 18 FDG-PET/CT images from control animal #DGT7 and GC treated animal #DHXD. D) Quantification of the lung lesion volume (dot size) and the metabolic intensity (normalized FDG uptake = SUV of lesion/SUV muscle). Significance calculated with 2way Anova multiple comparison test at the indicated timepoints between GC treatment and control. E) Quantification of subgenomic RNA <t>of</t> <t>the</t> <t>SARS-CoV-2</t> N1 protein in copies per mL of BAL fluid. Individual animals and the mean of each group with standard error mean represented. Significance calculated with 2way Anova. Fold change between GC treatment and control indicated. Limit of detection (LOD) is 2,000 copies/mL fluid. F) Subgenomic N1 in copies per gram of tissue in the pulmonary lymph nodes, PET+ involved lung, and PET- uninvolved lung. Significance calculated with 2way Anova multiple comparison test. LOD is 1,000 copies per gram of tissue. p > 0.05 not shown, *p < 0.05, ***p < 0.001.
Peptivator Sars Cov 2 Prot S Complete Wildtype Spike Peptide Pool, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peptivator sars cov 2 prot s complete wildtype spike peptide pool/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
peptivator sars cov 2 prot s complete wildtype spike peptide pool - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

95
Addgene inc sars cov 2 omicron ba 1 spike
a Representative images of syncytia formation assay in VeroE6 cells upon treatment (350 µM) with K5 compounds. Scale bar: 50 µm. b Number of nuclei involved in syncytia formation is higher in Wuhan-Hu-1 spike-positive cells than in <t>Omicron</t> <t>BA.1</t> spike-positive cells. c Effect of K5 compounds on syncytia formation induced by Wuhan-Hu-1 spike. d Effect of K5 compounds on syncytia formation induced by Omicron BA.1 spike. Only spike-positive cells were quantified. Data of four (Wuhan-Hu-1) and three (Omicron BA.1) independent experiments. Values are mean ± sd. P values determined by Welch’s t-test: * P < 0.05; ** P < 0.005.
Sars Cov 2 Omicron Ba 1 Spike, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars cov 2 omicron ba 1 spike/product/Addgene inc
Average 95 stars, based on 1 article reviews
sars cov 2 omicron ba 1 spike - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

95
Addgene inc sars cov 2 spike receptor binding domain deep mutational scanning library
a Representative images of syncytia formation assay in VeroE6 cells upon treatment (350 µM) with K5 compounds. Scale bar: 50 µm. b Number of nuclei involved in syncytia formation is higher in Wuhan-Hu-1 spike-positive cells than in <t>Omicron</t> <t>BA.1</t> spike-positive cells. c Effect of K5 compounds on syncytia formation induced by Wuhan-Hu-1 spike. d Effect of K5 compounds on syncytia formation induced by Omicron BA.1 spike. Only spike-positive cells were quantified. Data of four (Wuhan-Hu-1) and three (Omicron BA.1) independent experiments. Values are mean ± sd. P values determined by Welch’s t-test: * P < 0.05; ** P < 0.005.
Sars Cov 2 Spike Receptor Binding Domain Deep Mutational Scanning Library, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars cov 2 spike receptor binding domain deep mutational scanning library/product/Addgene inc
Average 95 stars, based on 1 article reviews
sars cov 2 spike receptor binding domain deep mutational scanning library - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

Image Search Results


A) Experimental design and sample collection. Created in part with BioRender under CC BY license, Nelson, C., (2025). B) Quantification of total lung lesions detected with 18 FDG-PET/CT imaging at the peak of the response, per animal and per group with mean. Animal #ID represented by color and shape in legend. C) Example 18 FDG-PET/CT images from control animal #DGT7 and GC treated animal #DHXD. D) Quantification of the lung lesion volume (dot size) and the metabolic intensity (normalized FDG uptake = SUV of lesion/SUV muscle). Significance calculated with 2way Anova multiple comparison test at the indicated timepoints between GC treatment and control. E) Quantification of subgenomic RNA of the SARS-CoV-2 N1 protein in copies per mL of BAL fluid. Individual animals and the mean of each group with standard error mean represented. Significance calculated with 2way Anova. Fold change between GC treatment and control indicated. Limit of detection (LOD) is 2,000 copies/mL fluid. F) Subgenomic N1 in copies per gram of tissue in the pulmonary lymph nodes, PET+ involved lung, and PET- uninvolved lung. Significance calculated with 2way Anova multiple comparison test. LOD is 1,000 copies per gram of tissue. p > 0.05 not shown, *p < 0.05, ***p < 0.001.

Journal: PLOS One

Article Title: Glucocorticoids suppress early lung inflammation and impair control of SARS-CoV-2 in non-human primates

doi: 10.1371/journal.pone.0342849

Figure Lengend Snippet: A) Experimental design and sample collection. Created in part with BioRender under CC BY license, Nelson, C., (2025). B) Quantification of total lung lesions detected with 18 FDG-PET/CT imaging at the peak of the response, per animal and per group with mean. Animal #ID represented by color and shape in legend. C) Example 18 FDG-PET/CT images from control animal #DGT7 and GC treated animal #DHXD. D) Quantification of the lung lesion volume (dot size) and the metabolic intensity (normalized FDG uptake = SUV of lesion/SUV muscle). Significance calculated with 2way Anova multiple comparison test at the indicated timepoints between GC treatment and control. E) Quantification of subgenomic RNA of the SARS-CoV-2 N1 protein in copies per mL of BAL fluid. Individual animals and the mean of each group with standard error mean represented. Significance calculated with 2way Anova. Fold change between GC treatment and control indicated. Limit of detection (LOD) is 2,000 copies/mL fluid. F) Subgenomic N1 in copies per gram of tissue in the pulmonary lymph nodes, PET+ involved lung, and PET- uninvolved lung. Significance calculated with 2way Anova multiple comparison test. LOD is 1,000 copies per gram of tissue. p > 0.05 not shown, *p < 0.05, ***p < 0.001.

Article Snippet: Peptide pool consisted of Peptivator SARS-CoV-2 Prot_S Complete (Miltenyi Cat#130-127-953), Peptivator SARS-CoV-2 Prot_S B.1.617.2 Mutation (Miltenyi Cat#130-128-763), and Peptivator SARS-CoV-2 Prot_N (Miltenyi Cat# 130-126-699).

Techniques: Positron Emission Tomography-Computed Tomography, Imaging, Control, Comparison

A) Representative flow cytometry of SARS-CoV-2 specific CD4 and CD8 T cell responses (IFNγ + /TNF+) in blood at day 7 post-infection after ex vivo peptide stimulation with Spike and Nucleocapsid peptide pools, gated on live/CD45 + /CD3 + /CD95 + . B) Quantification of the frequency of SARS-CoV-2 specific CD4 and CD8 T cell responses in the blood overtime after subtracting background staining in unstimulated samples. Significance calculated with 2-way Anova and multiple comparison test. C) Representative flow cytometry of SARS-CoV-2 specific CD4 and CD8 T cell responses (IFNγ + /TNF+) in BAL at day 13 post-infection after ex vivo peptide stimulation with Spike and Nucleocapsid peptide pools, gated on live/CD45 + /CD3 + /CD95 + . D) Quantification of the frequency of SARS-CoV-2 specific CD4 and CD8 T cell responses in the BAL overtime after subtracting background staining in unstimulated samples. Significance calculated with 2-way Anova and multiple comparison test. E) Geometric mean fluorescence intensity (GMFI) of IFNγ production by IFNγ + SARS-CoV-2 specific CD4 and CD8 T cells. F) GMFI of TNF production by TNF+ SARS-CoV-2 specific CD4 and CD8 T cells. G) Frequency of IL-2+ of SARS-CoV-2 specific (IFNγ + /TNF+) CD4 and CD8 T cells in the BAL at day 13 post-infection. Significance calculated with unpaired t-test. H) Frequency of Granzyme B+ of SARS-CoV-2 specific (IFNγ + /TNF+) CD4 and CD8 T cells in the BAL at day 13 post-infection. I) Frequency of IL-17A+ of SARS-CoV-2 specific (IFNγ + /TNF+) CD4 and CD8 T cells in the BAL at day 13 post-infection. p > 0.05 ns or not shown, *p < 0.05, ***p < 0.001. ****p < 0.000.

Journal: PLOS One

Article Title: Glucocorticoids suppress early lung inflammation and impair control of SARS-CoV-2 in non-human primates

doi: 10.1371/journal.pone.0342849

Figure Lengend Snippet: A) Representative flow cytometry of SARS-CoV-2 specific CD4 and CD8 T cell responses (IFNγ + /TNF+) in blood at day 7 post-infection after ex vivo peptide stimulation with Spike and Nucleocapsid peptide pools, gated on live/CD45 + /CD3 + /CD95 + . B) Quantification of the frequency of SARS-CoV-2 specific CD4 and CD8 T cell responses in the blood overtime after subtracting background staining in unstimulated samples. Significance calculated with 2-way Anova and multiple comparison test. C) Representative flow cytometry of SARS-CoV-2 specific CD4 and CD8 T cell responses (IFNγ + /TNF+) in BAL at day 13 post-infection after ex vivo peptide stimulation with Spike and Nucleocapsid peptide pools, gated on live/CD45 + /CD3 + /CD95 + . D) Quantification of the frequency of SARS-CoV-2 specific CD4 and CD8 T cell responses in the BAL overtime after subtracting background staining in unstimulated samples. Significance calculated with 2-way Anova and multiple comparison test. E) Geometric mean fluorescence intensity (GMFI) of IFNγ production by IFNγ + SARS-CoV-2 specific CD4 and CD8 T cells. F) GMFI of TNF production by TNF+ SARS-CoV-2 specific CD4 and CD8 T cells. G) Frequency of IL-2+ of SARS-CoV-2 specific (IFNγ + /TNF+) CD4 and CD8 T cells in the BAL at day 13 post-infection. Significance calculated with unpaired t-test. H) Frequency of Granzyme B+ of SARS-CoV-2 specific (IFNγ + /TNF+) CD4 and CD8 T cells in the BAL at day 13 post-infection. I) Frequency of IL-17A+ of SARS-CoV-2 specific (IFNγ + /TNF+) CD4 and CD8 T cells in the BAL at day 13 post-infection. p > 0.05 ns or not shown, *p < 0.05, ***p < 0.001. ****p < 0.000.

Article Snippet: Peptide pool consisted of Peptivator SARS-CoV-2 Prot_S Complete (Miltenyi Cat#130-127-953), Peptivator SARS-CoV-2 Prot_S B.1.617.2 Mutation (Miltenyi Cat#130-128-763), and Peptivator SARS-CoV-2 Prot_N (Miltenyi Cat# 130-126-699).

Techniques: Flow Cytometry, Infection, Ex Vivo, Staining, Comparison, Fluorescence

A) Quantification of total B cells (CD3 - /CD20 + ) by flow cytometry in the blood over time. Mean of each group with standard error mean (SEM) represented. Significance calculated with 2way Anova. B) Representative flow cytometry plots and gating strategy for identifying total B cells (CD3 - /CD20 + ) from the BAL at day 4 after infection. C) Quantification of total B cells by flow cytometry in the BAL over time. Mean, SEM, and 2way Anova. D) Quantification of total B cells by scRNAseq (cluster 9) in the BAL over time. Mean, SEM, and 2way Anova. E) Differentially expressed genes in B cells (cluster 9) at day 4 post-infection between GC treatment vs. control. Red is upregulated with GC treatment, log 2 FC > 1 and adjusted p-value <0.05. Blue is downregulated with GC treatment, log 2 FC < −1 and adjusted p-value <0.05. Grey with large dot is adjusted p-value <0.05 but absolute |log 2 FC| < 1. Grey with small dot is adjusted p-value >0.05. F) Representative flow cytometry plots and gating strategy for identifying naïve B cells (CD3 - /CD20 + /IgD + ) and activated B cell (CD3 - /CD20 + /IgD - /CD95 + ) from the BAL at day 4 after infection. G) Quantification of naïve B cells by flow cytometry in the BAL over time. Mean, SEM, and 2way Anova. H) Quantification of activated B cells by flow cytometry in the BAL over time. Mean, SEM, and 2way Anova. I) Quantification of total B cells, J) naïve B cells, K) and activated B cells in the spleen, bone marrow, axillary lymph nodes, and pulmonary lymph nodes at necropsy day 13 post-infection. Significance calculated with 2way Anova. L) Representative flow cytometry plots of Spike-specific B cells (CD3 - /CD20 + /CD95 + /Spike-tetramer + ) isolated from the axillary or pulmonary lymph nodes at necropsy, day 13 post-infection. M) Quantification of Spike-specific B cells (CD3 - /CD20 + /CD95 + /Spike (B.1.617.2) tetramer + ) as a percentage of non-naïve (IgD - ) B cells in the spleen, bone marrow, axillary lymph nodes, and pulmonary lymph nodes at necropsy day 13 post-infection. N) Quantification of the frequency of IgG + expression by Spike-specific (tetramer + ) B cells in the pulmonary lymph node. Significance calculated with 2way Anova. p > 0.05 ns or not shown, *p < 0.05, ***p < 0.001. ****p < 0.0001.

Journal: PLOS One

Article Title: Glucocorticoids suppress early lung inflammation and impair control of SARS-CoV-2 in non-human primates

doi: 10.1371/journal.pone.0342849

Figure Lengend Snippet: A) Quantification of total B cells (CD3 - /CD20 + ) by flow cytometry in the blood over time. Mean of each group with standard error mean (SEM) represented. Significance calculated with 2way Anova. B) Representative flow cytometry plots and gating strategy for identifying total B cells (CD3 - /CD20 + ) from the BAL at day 4 after infection. C) Quantification of total B cells by flow cytometry in the BAL over time. Mean, SEM, and 2way Anova. D) Quantification of total B cells by scRNAseq (cluster 9) in the BAL over time. Mean, SEM, and 2way Anova. E) Differentially expressed genes in B cells (cluster 9) at day 4 post-infection between GC treatment vs. control. Red is upregulated with GC treatment, log 2 FC > 1 and adjusted p-value <0.05. Blue is downregulated with GC treatment, log 2 FC < −1 and adjusted p-value <0.05. Grey with large dot is adjusted p-value <0.05 but absolute |log 2 FC| < 1. Grey with small dot is adjusted p-value >0.05. F) Representative flow cytometry plots and gating strategy for identifying naïve B cells (CD3 - /CD20 + /IgD + ) and activated B cell (CD3 - /CD20 + /IgD - /CD95 + ) from the BAL at day 4 after infection. G) Quantification of naïve B cells by flow cytometry in the BAL over time. Mean, SEM, and 2way Anova. H) Quantification of activated B cells by flow cytometry in the BAL over time. Mean, SEM, and 2way Anova. I) Quantification of total B cells, J) naïve B cells, K) and activated B cells in the spleen, bone marrow, axillary lymph nodes, and pulmonary lymph nodes at necropsy day 13 post-infection. Significance calculated with 2way Anova. L) Representative flow cytometry plots of Spike-specific B cells (CD3 - /CD20 + /CD95 + /Spike-tetramer + ) isolated from the axillary or pulmonary lymph nodes at necropsy, day 13 post-infection. M) Quantification of Spike-specific B cells (CD3 - /CD20 + /CD95 + /Spike (B.1.617.2) tetramer + ) as a percentage of non-naïve (IgD - ) B cells in the spleen, bone marrow, axillary lymph nodes, and pulmonary lymph nodes at necropsy day 13 post-infection. N) Quantification of the frequency of IgG + expression by Spike-specific (tetramer + ) B cells in the pulmonary lymph node. Significance calculated with 2way Anova. p > 0.05 ns or not shown, *p < 0.05, ***p < 0.001. ****p < 0.0001.

Article Snippet: Peptide pool consisted of Peptivator SARS-CoV-2 Prot_S Complete (Miltenyi Cat#130-127-953), Peptivator SARS-CoV-2 Prot_S B.1.617.2 Mutation (Miltenyi Cat#130-128-763), and Peptivator SARS-CoV-2 Prot_N (Miltenyi Cat# 130-126-699).

Techniques: Flow Cytometry, Infection, Control, Isolation, Expressing

a Representative images of syncytia formation assay in VeroE6 cells upon treatment (350 µM) with K5 compounds. Scale bar: 50 µm. b Number of nuclei involved in syncytia formation is higher in Wuhan-Hu-1 spike-positive cells than in Omicron BA.1 spike-positive cells. c Effect of K5 compounds on syncytia formation induced by Wuhan-Hu-1 spike. d Effect of K5 compounds on syncytia formation induced by Omicron BA.1 spike. Only spike-positive cells were quantified. Data of four (Wuhan-Hu-1) and three (Omicron BA.1) independent experiments. Values are mean ± sd. P values determined by Welch’s t-test: * P < 0.05; ** P < 0.005.

Journal: npj Viruses

Article Title: K5 polysaccharides inhibit SARS-CoV-2 infection by preventing spike-proteolytic priming

doi: 10.1038/s44298-025-00163-4

Figure Lengend Snippet: a Representative images of syncytia formation assay in VeroE6 cells upon treatment (350 µM) with K5 compounds. Scale bar: 50 µm. b Number of nuclei involved in syncytia formation is higher in Wuhan-Hu-1 spike-positive cells than in Omicron BA.1 spike-positive cells. c Effect of K5 compounds on syncytia formation induced by Wuhan-Hu-1 spike. d Effect of K5 compounds on syncytia formation induced by Omicron BA.1 spike. Only spike-positive cells were quantified. Data of four (Wuhan-Hu-1) and three (Omicron BA.1) independent experiments. Values are mean ± sd. P values determined by Welch’s t-test: * P < 0.05; ** P < 0.005.

Article Snippet: Plasmid encoding for SARS-CoV-2 Omicron BA.1 spike was kindly provided by Prof. Ralf Bartenschlager and purchased from Addgene (#180375).

Techniques: Tube Formation Assay

VeroE6 cells or A549 ACE2+ cells were treated with increasing concentrations of heparin, K5, K5OSH, and K5NOSH. a , b The cells remained viable in the presence of heparin and the K5 compounds as evaluated by measuring the ATP levels. VeroE6 or A549 ACE2+ cells were infected with the B.1 c , d or Omicron BA.1 e , f isolates in the presence or the absence of increasing concentrations of heparin, K5, K5OSH, and K5NOSH. Infection was reduced in a concentration-dependent manner as shown by the percentage of plaque reduction compared to SARS-CoV-2 alone. Data are presented as the mean value ± standard error of three independent replicates. * P < 0.05; ** P < 0.005.

Journal: npj Viruses

Article Title: K5 polysaccharides inhibit SARS-CoV-2 infection by preventing spike-proteolytic priming

doi: 10.1038/s44298-025-00163-4

Figure Lengend Snippet: VeroE6 cells or A549 ACE2+ cells were treated with increasing concentrations of heparin, K5, K5OSH, and K5NOSH. a , b The cells remained viable in the presence of heparin and the K5 compounds as evaluated by measuring the ATP levels. VeroE6 or A549 ACE2+ cells were infected with the B.1 c , d or Omicron BA.1 e , f isolates in the presence or the absence of increasing concentrations of heparin, K5, K5OSH, and K5NOSH. Infection was reduced in a concentration-dependent manner as shown by the percentage of plaque reduction compared to SARS-CoV-2 alone. Data are presented as the mean value ± standard error of three independent replicates. * P < 0.05; ** P < 0.005.

Article Snippet: Plasmid encoding for SARS-CoV-2 Omicron BA.1 spike was kindly provided by Prof. Ralf Bartenschlager and purchased from Addgene (#180375).

Techniques: Infection, Concentration Assay